BioCryst (BCRX) Stock Forecast & Price Target

Compare

2,419 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BCRX Analyst Ratings

Strong Buy

9 Buy

2 Hold

0 Sell

Based on 11 analysts giving stock ratings to

BioCryst

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BCRX Stock 12 Month Forecast

Average Price Target

$19.27

▲(154.56% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $19.27 with a high forecast of $30.00 and a low forecast of $8.00. The average price target represents a 154.56% change from the last price of $7.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","31":"$31","12.25":"$12.25","18.5":"$18.5","24.75":"$24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.25,18.5,24.75,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.13,8.88923076923077,10.64846153846154,12.407692307692308,14.166923076923077,15.926153846153845,17.685384615384617,19.444615384615386,21.203846153846154,22.963076923076922,24.72230769230769,26.481538461538463,28.24076923076923,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.13,8.063846153846153,8.997692307692308,9.931538461538462,10.865384615384615,11.79923076923077,12.733076923076922,13.666923076923077,14.600769230769231,15.534615384615385,16.46846153846154,17.402307692307694,18.336153846153845,{"y":19.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.13,7.196923076923077,7.263846153846154,7.3307692307692305,7.397692307692307,7.464615384615384,7.531538461538462,7.598461538461539,7.665384615384616,7.7323076923076925,7.799230769230769,7.866153846153846,7.933076923076923,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.25,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$19.27

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Serge Belanger

Needham

$18

Buy

137.78%

Upside

Reiterated

12/12/25

BioCryst's Growth Potential Bolstered by FDA Approval and Strategic Moves: A Buy Recommendation

Laura Chico

Wedbush

$21

Buy

177.41%

Upside

Reiterated

12/12/25

BioCryst (BCRX) Gets a Buy from Wedbush

Jonathan Wolleben

Citizens JMP

$27→$25

Buy

230.25%

Upside

Reiterated

11/05/25

BioCryst price target lowered to $25 from $27 at Citizens JMPBioCryst price target lowered to $25 from $27 at Citizens JMP

Andrew Fein

H.C. Wainwright

$30

Buy

296.30%

Upside

Reiterated

11/04/25

Analysts Offer Insights on Healthcare Companies: Caribou Biosciences (NASDAQ: CRBU), Santhera Pharmaceuticals Holding (Other OTC: SPHDF) and BioCryst (NASDAQ: BCRX)We reiterate our Buy rating and $30 price target.

Stacy Ku

TD Cowen

$30

Buy

296.30%

Upside

Reiterated

11/03/25

BioCryst's Orladeyo: Strong Growth and Strategic Moves Reinforce Buy RatingWe expect 2025 will reflect continued Orladeyo outperformance, and expect full year sales of $600MM (+37%). We believe investors should focus on the value discount for Orladeyo, with proposed Q1 ATXS acquisition to established BCRX as incumbent in HAE (here) - while maintaining profitability.BCRX is trading ~2x 2027E revenues, with IP through 2039. We believe the substantial disconnect reflects concern for the emerging development landscape - despite KOL views that Orladeyo will steadily grow, with high KOL enthusiasm for navenibart. Our KOLs expect use for both oral and injectable prophylaxis, and a split in preference of 60-70% injectable/30-40% oral (survey here). We expect navenibart can capture ~20% of HAE prophylaxis patients to achieve $1B in sales, even while sharing the HAE market with other injectable/oral options.

Brian Abrahams

RBC Capital

$15

Buy

98.15%

Upside

Reiterated

11/03/25

RBC Capital Remains a Buy on BioCryst (BCRX)

Tazeen Ahmad

Bank of America Securities

$15

Buy

98.15%

Upside

Reiterated

11/03/25

BioCryst's Strong Growth and Strategic Moves Reinforce Buy Rating

Gena Wang

Barclays

$11→$9

Hold

18.89%

Upside

Reiterated

11/03/25

Barclays Sticks to Their Hold Rating for BioCryst (BCRX)

Steven Seedhouse

Cantor Fitzgerald

$24→$26

Buy

243.46%

Upside

Reiterated

10/15/25

Cantor Fitzgerald Remains a Buy on BioCryst (BCRX)Cantor Fitzgerald analyst Steven Seedhouse raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $26.00 (from $24.00) while maintaining an Overweight rating.

Maury Raycroft

Jefferies

$15

Buy

98.15%

Upside

Reiterated

10/14/25

BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and ProfitabilityWe added naven to our model (50% POS). PT to $15.

Gavin Clark-Gartner

Evercore ISI

$12→$8

Hold

5.68%

Upside

Downgraded

10/01/25

BioCryst downgraded to In Line from Outperform at Evercore ISIBioCryst downgraded to In Line from Outperform at Evercore ISI

Jessica Fye

J.P. Morgan

$10→$13

Buy

71.73%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Serge Belanger

Needham

$18

Buy

137.78%

Upside

Reiterated

12/12/25

BioCryst's Growth Potential Bolstered by FDA Approval and Strategic Moves: A Buy Recommendation

Laura Chico

Wedbush

$21

Buy

177.41%

Upside

Reiterated

12/12/25

BioCryst (BCRX) Gets a Buy from Wedbush

Jonathan Wolleben

Citizens JMP

$27→$25

Buy

230.25%

Upside

Reiterated

11/05/25

BioCryst price target lowered to $25 from $27 at Citizens JMPBioCryst price target lowered to $25 from $27 at Citizens JMP

Andrew Fein

H.C. Wainwright

$30

Buy

296.30%

Upside

Reiterated

11/04/25

Stacy Ku

TD Cowen

$30

Buy

296.30%

Upside

Reiterated

11/03/25

Brian Abrahams

RBC Capital

$15

Buy

98.15%

Upside

Reiterated

11/03/25

RBC Capital Remains a Buy on BioCryst (BCRX)

Tazeen Ahmad

Bank of America Securities

$15

Buy

98.15%

Upside

Reiterated

11/03/25

BioCryst's Strong Growth and Strategic Moves Reinforce Buy Rating

Gena Wang

Barclays

$11→$9

Hold

18.89%

Upside

Reiterated

11/03/25

Barclays Sticks to Their Hold Rating for BioCryst (BCRX)

Steven Seedhouse

Cantor Fitzgerald

$24→$26

Buy

243.46%

Upside

Reiterated

10/15/25

Maury Raycroft

Jefferies

$15

Buy

98.15%

Upside

Reiterated

10/14/25

BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and ProfitabilityWe added naven to our model (50% POS). PT to $15.

Gavin Clark-Gartner

Evercore ISI

$12→$8

Hold

5.68%

Upside

Downgraded

10/01/25

BioCryst downgraded to In Line from Outperform at Evercore ISIBioCryst downgraded to In Line from Outperform at Evercore ISI

Jessica Fye

J.P. Morgan

$10→$13

Buy

71.73%

Upside

Reiterated

05/06/25

J.P. Morgan Remains a Buy on BioCryst (BCRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioCryst

1 Month

xxx

Success Rate

16/28 ratings generated profit

Average Return

+0.93%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +0.93% per trade.

3 Months

xxx

Success Rate

10/19 ratings generated profit

Average Return

+1.15%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 52.63% of your transactions generating a profit, with an average return of +1.15% per trade.

1 Year

Brian AbrahamsRBC Capital

Success Rate

11/19 ratings generated profit

Average Return

+12.28%

reiterated a buy rating last month

Copying Brian Abrahams's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +12.28% per trade.

2 Years

xxx

Success Rate

13/19 ratings generated profit

Average Return

+9.06%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +9.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCRX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BCRX has received 21 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. BCRX average Analyst price target in the past 3 months is 19.27.

Each month's total comprises the sum of three months' worth of ratings.

BCRX Financial Forecast

BCRX Earnings Forecast

Next quarter’s earnings estimate for BCRX is $0.03 with a range of $0.00 to $0.07. The previous quarter’s EPS was $0.06. BCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.

BCRX Sales Forecast

Next quarter’s sales forecast for BCRX is $150.44M with a range of $145.14M to $156.03M. The previous quarter’s sales results were $159.40M. BCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.

BCRX Stock Forecast FAQ

What is BCRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Biocryst Pharmaceuticals’s 12-month average price target is 19.27.

What is BCRX’s upside potential, based on the analysts’ average price target?

Biocryst Pharmaceuticals has 154.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BCRX a Buy, Sell or Hold?

Biocryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 9 buy ratings, 2 hold ratings and 0 sell ratings.

What is Biocryst Pharmaceuticals’s price target?

The average price target for Biocryst Pharmaceuticals is 19.27. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $8.00. The average price target represents 154.56% Increase from the current price of $7.57.

What do analysts say about Biocryst Pharmaceuticals?

Biocryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of BCRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioCryst (BCRX) Stock Forecast & Price Target

BCRX Analyst Ratings

BCRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioCryst

BCRX Analyst Recommendation Trends

BCRX Financial Forecast

BCRX Earnings Forecast

BCRX Sales Forecast

BCRX Stock Forecast FAQ

Detailed List of Analyst Forecasts